Form 4: Tvardi Therapeutics Director Wyzga Acquires Stock Options

Michael S. Wyzga, a director at Tvardi Therapeutics, acquired 12,000 stock options on April 17, 2025, according to a Form 4 filing with the SEC.

Summary

• Michael S. Wyzga, a director of Tvardi Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on April 17, 2025, where Wyzga acquired 12,000 stock options.
• The exercise price of the options is $17.04.
• The options vest in 12 equal quarterly installments over three years, starting July 17, 2025, contingent upon continuous service.
• The options expire on April 16, 2035.
• Following the transaction, Wyzga directly owns 12,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of options by a director is generally viewed as a positive, but it's a routine filing.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a positive signal.

Key Dates

Keywords

Form 4, Tvardi Therapeutics, Stock Options, Director, Beneficial Ownership, Wyzga, TVRD